Vis enkel innførsel

dc.contributor.authorMartinuzzi, Emanuela
dc.contributor.authorBarbosa, Susana
dc.contributor.authorDaoudlarian, Douglas
dc.contributor.authorBel Haj Ali, Wafa
dc.contributor.authorGilet, Cyprien
dc.contributor.authorFillatre, Lionel
dc.contributor.authorKhalfallah, Olfa
dc.contributor.authorTroudet, Réjane
dc.contributor.authorJamain, Stéphane
dc.contributor.authorFond, Guillaume
dc.contributor.authorSommer, Iris Else Clara
dc.contributor.authorLeucht, Stefan
dc.contributor.authorDazzan, Paola
dc.contributor.authorMcGuire, Philip
dc.contributor.authorArango, Celso
dc.contributor.authorDiaz-Caneja, Covadonga M.
dc.contributor.authorFleischhacker, Wolfgang
dc.contributor.authorRujescu, Dan
dc.contributor.authorGlenthøj, Birte
dc.contributor.authorWinter, Inge
dc.contributor.authorKahn, René Sylvain
dc.contributor.authorYolken, Robert
dc.contributor.authorLewis, Shon
dc.contributor.authorDrake, Richard
dc.contributor.authorDavidovic, Laetitia
dc.contributor.authorLeboyer, Marion
dc.contributor.authorGlaichenhaus, Nicolas
dc.PublishedTranslational Psychiatry. 2019, 9: 20.en_US
dc.description.abstractEarly response to first-line antipsychotic treatments is strongly associated with positive long-term symptomatic and functional outcome in psychosis. Unfortunately, attempts to identify reliable predictors of treatment response in first-episode psychosis (FEP) patients have not yet been successful. One reason for this could be that FEP patients are highly heterogeneous in terms of symptom expression and underlying disease biological mechanisms, thereby impeding the identification of one-size-fits-all predictors of treatment response. We have used a clustering approach to stratify 325 FEP patients into four clinical subtypes, termed C1A, C1B, C2A and C2B, based on their symptoms assessed using the Positive and Negative Syndrome Scale (PANSS) scale. Compared to C1B, C2A and C2B patients, those from the C1A subtype exhibited the most severe symptoms and were the most at risk of being non-remitters when treated with the second-generation antipsychotic drug amisulpride. Before treatment, C1A patients exhibited higher serum levels of several pro-inflammatory cytokines and inflammation-associated biomarkers therefore validating our stratification approach on external biological measures. Most importantly, in the C1A subtype, but not others, lower serum levels of interleukin (IL)-15, higher serum levels of C-X-C motif chemokine 12 (CXCL12), previous exposure to cytomegalovirus (CMV), use of recreational drugs and being younger were all associated with higher odds of being non-remitters 4 weeks after treatment. The predictive value of this model was good (mean area under the curve (AUC) = 0.73 ± 0.10), and its specificity and sensitivity were 45 ± 0.09% and 83 ± 0.03%, respectively. Further validation and replication of these results in clinical trials would pave the way for the development of a blood-based assisted clinical decision support system in psychosis.en_US
dc.publisherSpringer Natureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleStratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright The Author(s) 2019en_US
dc.source.articlenumber20 (2019)en_US
dc.source.journalTranslational Psychiatryen_US
dc.identifier.citationTranslational Psychiatry. 2019, 9, 20.

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal